RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
IHREC Says Child Trafficking Is Under-Identified In Ireland
TikTok Says It Has Removed Less Than 30 Videos Related To Wrong-Way Driving Since M9 Crash In Moone
Man (29) Remanded On Bail For Allegedly Driving His Car At Numerous People In Skerries
Minister Lawless Pushes For Rent-A-Room Scheme Expansion
Tánaiste Indicates Carbon Tax Cuts On Home-Heating Oil
Seven In Ten Young Adults Considering Emigrating
Research Highlights High Level Of Energy Drink Consumption Among Young People
Taoiseach And Ministers To Travel To New York For UN General Assembly
